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Abstract
Functionalized oligonucleotides have recently gained increased attention for incorporation in modified nucleic acid structures both
for the design of aptamers with enhanced binding properties as well as the construction of catalytic DNA and RNA. As a shortcut
alternative to the incorporation of multiple modified residues, each bearing one extra functional group, we present here a straight-
forward method for direct linking of functionalized amino acids to the nucleoside base, thus equipping the nucleoside with two
extra functionalities at once. As a proof of principle, we have introduced three amino acids with functional groups frequently used
as key-intermediates in DNA- and RNAzymes via an efficient and straightforward domino carboxamidation reaction.
Introduction
For decades DNA has been known as the carrier of the genetic
information. Only recently, the use of synthetic oligonu-
cleotides and their modified analogues for a range of thera-
peutic and diagnostic purposes [1], including antisense therapy
[2,3], antigene therapy [4,5] and SNP (Single Nucleotide Poly-
morphism) detection [6] has gained major interest. Due to their
predictable and well-investigated structure, the strength of
nucleic acids for a series of applications such as DNA and RNA
based drugs [7], drug delivery systems [8,9], DNA-biosensors
[10,11] and potential catalysts has now firmly been recognized.
Rather than using unmodified oligonucleotides, providing addi-
tional functional groups can lead to even higher activities and
selectivities. Indeed, people have realized that equipping the
nucleic acid scaffold with protein side chain-like moieties may
assist in the design of a broad scope of functionalized oligonu-
cleotides with various characteristics. This can be enabled by
techniques such as solid phase synthesis, post synthetic modifi-
cations or enzymatic incorporation of modified analogues.
Originating from research into aptamers as strong and selective
binders [12-14], several research groups are investigating the
creation and synthesis of new DNA or RNA catalysts, also
called DNAzymes [15-17] and RNAzymes [10,16,18-21], res-
pectively. Most catalytic nucleic acids are generated using the
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Figure 1: Amino acid functionalized nucleosides.
SELEX (Systematic Evolution of Ligands by EXponential
enrichment) protocol [22-25] that generates a library of poten-
tial catalysts, which are then screened for catalytic potential
using natural substrates or transition state analogues. Although
examples [26-29] exist illustrating the introduction of modified
residues and by that the development of new catalysts, the
SELEX protocol becomes more labor intensive and repro-
ducibility of results is often a problem. Moreover achieving
control in terms of number, positioning and exact location of
the desired catalytic moieties is far from straightforward. In
contrast to the existing variety of rather complicated and unpre-
dictable RNA based ribozyme-like structures, oligonucleotide
duplexes have a stable and predictable structure allowing the
design of engineered active sites through the carefully planned
introduction of extra catalytic functionalities via solid phase
DNA synthesis. We have further recently shown that the combi-
nation of solid phase synthesis and molecular modeling
combined with advanced NMR techniques offers the possibility
to predict and control the positioning of catalytic functions
within a DNA duplex [30].
Chemical modification of nucleic acids can be performed on
different positions, including the backbone, the sugar unit and
the heterocyclic base, whereby base modification is the most
common as it causes only minor disturbance in the helical struc-
ture [31]. Depending on the position of the incorporation on the
nucleoside structure, the introduced functionalities can be
pointed towards the major or the minor groove of the duplex.
Modification of position 1’ and 2’ will orient substituents
towards the minor groove while positions 5, 7 and 8 on the base
allow directing incorporated substituents in the major groove.
One can further imagine that introduction of extra functionali-
ties can have an impact on the duplex stability and final struc-
ture of the double helix. This was illustrated in previous
research in our laboratory where introduction of modified
nucleosides on the 2’-position in a DNA double helix resulted
in a destabilization of the duplex of 5 °C per modified unit [32].
Although this destabilization depends on many different
aspects, such as the type and length of the linker and the pos-
ition of the modification, it is important to minimize destabiliza-
tion as much as possible, more specifically when introduction of
more than one modification is desired. To date most research
groups have focused on the introduction of only one extra func-
tionality per nucleoside, mainly for synthetic reasons, and
preferably making use of commercially available building
blocks. We therefore considered the incorporation of moieties
containing multiple functionalities on a nucleoside residue and
present a straightforward method for the introduction of side
chain functionalized amino acids onto nucleoside building
blocks (Figure 1). Following the event of solid phase peptide
synthesis, a large range of amino acids with different protection
schemes and stereochemistry is currently commercially avail-
able. We here illustrate a methodology for direct incorporation
of amino acids via a short synthetic pathway offering the added
benefit of introducing multiple functional groups at the same
time.
Indeed, whereas the α-amino group is used to ensure linkage to
the nucleoside building block, both the side chain functional
group and the α-carboxylate end up as extra functionalities on
the nucleoside. As proof of principle and with the catalytic
serine–histidine–aspartate catalytic triad of serine proteases in
mind, we illustrate the preparation of three different nucleo-
sides equipped with three functional amino acids containing
hydroxy, imidazole, amine and carboxylate groups for later
incorporation into nucleic acid duplexes via solid phase DNA
synthesis [33].
Results and Discussion
As mentioned earlier, a number of research groups have used
the SELEX or in vitro selection protocol for the incorporation
of amino acid-like modifications into DNA or RNA where there
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Scheme 1: Reagents and conditions: a) i. Et3N, Pd(PPh3)4, THF, CO (4 bar), 70 °C, 48 h, ii. Et3N, di-tert-butyl dicarbonate, DMF, rt, 15 min (79%);
b) Et3N·3HF, Et3N, THF, rt, overnight (72%); c) DMTr-Cl, pyridine, 0 °C, 7 h (52%).
is no need for protection of the functional groups. For example,
many imidazole and amine functionalities were incorporated to
increase the structural diversity and catalytic potential of
nucleic acids [34-37]. Most of these functionalities are intro-
duced into the triphosphate building blocks using palladium-
based coupling chemistry to the pyrimidine C5 or the 7-pos-
ition of 7-deaza-2’-deoxyadenosine [38-40]. During enzymatic
incorporation the extra functionalities do not need to be
protected. However, solid phase DNA synthesis implies an
appropriate protection of the extra functionalities on the corres-
ponding nucleoside building blocks to avoid side-reactions
during DNA synthesis. Not only should these protecting groups
be stable under all chemical conditions used in the synthesis
pathway, they should also be stable under the DNA synthesis
conditions and easily removable after assembly of the desired
chain without DNA damage.
In the current study, we have chosen to couple three amino
acids, which contain functional groups commonly used in
SELEX approaches to modify DNA or RNA, to 5-iodo-2’-
deoxyuridine. We describe the direct and linker-less introduc-
tion of histidine, serine and lysine derivatives onto nucleosides
via a straightforward and easy domino carboxamidation reac-
tion. Previously the groups of Gait and Eaton [41-43] have used
this reaction to couple histamine or simple amine derivatives to
both 5-iodo-2’-deoxyuridine and purine nucleosides. Although
a large number of imidazole modified pyrimidine and purine
derivatives for solid phase synthesis have been described to date
[41,44-47], we believe that the reactions described here serve as
an ideal model system, which can be extended to other commer-
cially available amino acid derivatives and nucleosides.
For the introduction of histidine onto the nucleoside as shown in
Scheme 1, we chose to protect the free 3’ and 5’-hydroxy
groups with tert-butyldimethylsilyl (TBDMS) groups 1 to avoid
side reactions during the next step, the carboxamidation reac-
tion [48]. While protected histidine is commercially available,
we have synthesized histidine as a methyl ester (2) with thionyl
chloride in methanol in good yield according to literature pro-
cedures [49]. Although basic hydrolysis of alkyl esters has been
shown to imply long reaction times, side-product formation and
low reaction yields [50], we found that methyl esters within
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Scheme 2: Reagents and conditions: a) Et3N, Pd(PPh3)4, THF, CO (4 bar), 48 h, 70 °C (68%); b) Et3N·3HF, Et3N, THF, overnight, rt (86%);
c) DMTr-Cl, pyridine, DCM, overnight, rt (82%).
DNA are hydrolysed under basic conditions even at room
temperature using aqueous ammonia provided prolonged reac-
tion times are respected [51]. Inspired by the results of Perrin
and Joyce [26,52], who introduced a nucleoside containing an
unprotected imidazole functionality into the DNA synthesis
cycle without problems, we first tried to leave the imidazole
unprotected in order to avoid extra protection and deprotection
steps in the reaction sequence. However, in view of problems
arising during the separation by column chromatography after
the CO insertion reaction with an unprotected histidine methyl
ester, we decided to protect the imidazole functionality immedi-
ately after the reaction with the tert-butyloxycarbonyl (t-Boc)
protecting group [53], which is compatible with the reagents
used during nucleoside- and oligonucleotide synthesis [45,54].
While the t-Boc group can be removed with a 10% TFA solu-
tion [54], the acid labile DNA can suffer from depurination
after treatment with acid. According to literature, the t-Boc
group can also be cleaved during standard deprotection pro-
cedures with saturated ammonia after oligonucleotide synthesis
[41,55]. In view of all these considerations, coupling of the
TBDMS-protected nucleoside 1 with histidine methyl ester 2
followed by in situ t-Boc protection of the free hydrogen on the
imidazole functionality gave the desired compound 3 in satis-
fying yield.
In the next step of the synthesis, the TBDMS-protecting groups
needed to be removed. First attempts using tetra-butylammo-
nium fluoride (TBAF) resulted in degradation of the starting
material (results not shown). Indeed, several reports in litera-
ture highlight the strong basic character of the fluoride anion
(F−) that can cause decomposition of or nucleophilic attack on
the nucleoside [56,57]. Manfredini et al. have shown that selec-
tive deprotection of the TBDMS groups in the presence of a
t-Boc protecting group is possible when using Et3N·3HF [58]
and also in our case using Et3N·3HF in THF resulted in product
4 with good purity and yield (72%) [59]. Dimethoxytritylation
could be accomplished under standard conditions and the
corresponding derivative 5 was isolated and purified without
problems.
As a second example we decided to employ serine as amino
acid for introduction onto the nucleoside. In view of the earlier
illustrated need for imidazole protection during introduction of
histidine (vide supra), we used commercially available benzyl
protected serine 6 to avoid problems due to the free hydroxy
group of the serine during the carboxamidation reaction
(Scheme 2). After DNA synthesis, the benzyl group can be
cleaved using hydrogen and palladium on carbon. To avoid
overreduction of the pyrimidine double bond, transfer hydro-
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Scheme 3: Reagents and conditions: a) Et3N, Pd(PPh3)4, THF, CO (4 bar), 48 h, 70 °C (90%); b) Et3N·3HF, Et3N, THF, overnight, rt (43%);
c) DMTr-Cl, pyridine, DCM, overnight, rt (9%).
genation with cyclohexene as hydrogen source and 10% palla-
dium on carbon should be used [60-62]. As the methyl ester
derivative of the amino acid is commercially available but
rather expensive, we performed the esterification reaction on
the benzyl protected serine to deliver product 6 in good yield
and purity after recrystallization in cold diethyl ether (64%)
[63]. Coupling of protected serine methyl ester 6 with TBDMS-
protected nucleoside 1 in the presence of tetrakis(triphenylphos-
phine)palladium(0) and Et3N in THF under CO atmosphere
(4 bar) gave the desired product 7. After deprotection of the
TBDMS groups to yield 8 under similar reaction conditions as
used before to obtain product 4, the free 5’-hydroxy group was
selectively protected with DMTr-Cl to obtain the modified
desired nucleoside 9 in good yield and purity.
As the functional groups of histidine (imidazole) and lysine
(cationic amine) are known to be present in numerous enzyme
active sites and capable of general acid–general base catalysis,
we have finally chosen to modify a nucleoside with a lysine
amino acid derivative as a third example of our current strategy,
as shown in Scheme 3. Protected lysine 10 is commercially
available and was coupled with the TBDMS-protected nucleo-
side 1 to afford product 11 in high yield. After deprotection
of the tert-butyldimethylsilyl protecting groups using the
above described protocol, modified nucleoside 12 could be
selectively protected at the free 5’-hydroxy group with
DMTr-Cl to afford 13. Compared to the previous reaction
schemes, this final reaction suffers more from the steric
hindrance as compared to the other amino acids that show less
bulky substituents.
Conclusion
We here illustrated the efficient application of a simple carbox-
amidation procedure for the synthesis of modified nucleosides
featuring two extra functional groups. Because hydrolysis of the
methyl ester and removal of the t-Boc is performed during the
standard cleavage of solid support using NH4OH and benzyl
and benzoyl protecting groups can be removed by hydrogena-
tion [64], only one extra deprotection step is needed after
incorporation. After transformation of the modified nucleosides
into the corresponding phosphoramidite building blocks 5, 9
and 13 are amenable to incorporation in nucleic acids through
standard DNA synthesis methodology. The described protocol
relies on commercially available amino acid derivatives and
should be applicable to a large series of natural and unnatural
amino acids.
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